Technological and pharmacoeconomic aspects of the development of drug for the complex therapy of acute intestinal infections

Authors

DOI:

https://doi.org/10.24959/uekj.20.27

Keywords:

pharmacy, combined drug, technology, acute intestinal infections

Abstract

Today combination drugs are widely used to treat acute intestinal infections (AII). Acute intestinal infections requiring comprehensive treatment with antimicrobial drugs, enterosorbents, pro- and prebiotics and immune drugs. We have developed the composition and technology of drug wchich contain nifuroxazide and plant substance plantaglucid. This combination is a modern treatment of AII, because it combination has high efficiency, safety, availability and comfortable use.

The purpose of the research was development of composition and technological scheme of the original combined drug in the form of capsules “Diaplant” for the complex treatment AII and the study of its pharmacoeconomic aspects.

Results and discussion. The combination of nifuroxazide with plantaglucid, which has additional microbiological and pharmacological effects, was justified. To develop of the composition and technology this combined drug, the technology of separate preparation of masses for encapsulation with using excipients of different groups was used. The technological scheme of production of “Diaplant” capsules is developed and the specification for quality control of capsules is made. ATC/DDD-methodology showed that the cost for DDD of “Diaplant” was 14,54 UAH. The total cost of the average recommended daily doses of separate drugs (nifuroxazide and Plantaglucidum) ranged from 22,13 to 38,05 UAH. The use of “Diaplant” in clinical practice allows reducing the cost of pharmacotherapy of AII from 152 to 262 %.

Conclusion. The technological scheme of production of the domestic drug in capsules “Diaplant” that contains nifuroxazide and Plantaglucidum was developed for pharmacotherapy of acute intestinal infections. The developed drug “Diaplant” has high antimicrobial, anti-inflammatory, antispasmodic and detoxic activity, normalizes intestinal motility and helps to restore the intestinal microflora.

References

Nifuroxazid LLC Ternofarm is a study of efficiency and safety. (2011). Ukrainskyi medychnyi chasopys, 3 (83), V/VI. Available at: www.umj.com.ua.

Germanyuk, T., Bobrytska, L., Ivko, T., Fares, R. (2019). Diaplant: development of technology and pharmacoeconomic evidence of therapy. Lambert Academic Publishing of International Book Market Service Ltd, 60.

Nazarova, O. S., Verbova, Yu. M., Kazarinov, M. O., Sidenko, L. M., Veselova O. A. (2015). Vivchennya kinetics rosinchinennya in vitro of Likarsky preparations with nifuroxazid at the form of capsules. Pharmacom, 3-4, 5-11

Olennikov, D. N., Samuelsen, A. B., Tankhaeva, L. M. (2007). Khimiia rastitelnogo syria, 2, 37–50.

Fares, R., Bobrytska, L., Germanyuk, T., Kryvoviaz, O., Ivko, T., Toziuk, O., Balicka, O., Bobrowska, O. (2017). Diaplant: Manufacturing technology and rationalization of costs of acute intestinal infection pharmacotherapy. International Journal of Green Pharmacy, 11 (3), 584-589. doi: http://dx.doi.org/10.22377/ijgp.v11i03.1178.

Kovaleva, Yu. S., Fares, R., Bobritckaia, L. A., Tolokonnikova, A. A. (2017). Proceeding from Promyslova farmatsіia: etapy stanovlennia ta maibutnie: materіaly mіzhnar. nauk-prakt. konf. (29-30 veres. 2017 r.). (pp. 66-69). Kharkіv: NFaU.

Fares, R., Bobritckaia, L. A., Osolodchenko, T. P., Gritcenko, V. I.(2016). Annals of Mechnikov Institute, 4, 112-115. Available at: www.imiamn.org.ua/journal.htm.

Fares, R., Bobrytska, L. A., Drogovoz, S. M., Popova, N. V., Shpychak, O. S, Hrytsenko, V. I., Ivko, T. I., Kononenko, A. V. (2017). Research of the pharmacological activity of capsules Diaplant. Likarska sprava, 8, 144-148.

Aslanian, M. A. et al. (2018). Development of the composition and manufacturing technology of the new combined drug Lavaflam. Turkish Journal of Pharmaceutical Sciences, 15 (3), 263-270.

Fares, R., Bobritckaia, L. A. (2016). Farmatsevticheskii zhurnal, 1, 72–78.

Downloads

Published

2020-09-10

Issue

No. 3(63) (2020)

Section

Quality, standardization and certification in pharmacy

License

Copyright (c) 2020 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:
  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторський договір